
Haileyesus Getahun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12202847/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	WHO's new End TB Strategy. Lancet, The, 2015, 385, 1799-1801.	13.7	834
2	Tuberculosis. Nature Reviews Disease Primers, 2016, 2, 16076.	30.5	830
3	Towards tuberculosis elimination: an action framework for low-incidence countries. European Respiratory Journal, 2015, 45, 928-952.	6.7	608
4	Latent <i>Mycobacterium tuberculosis</i> Infection. New England Journal of Medicine, 2015, 372, 2127-2135.	27.0	578
5	Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet, The, 2007, 369, 2042-2049.	13.7	486
6	Management of latent <i>Mycobacterium tuberculosis</i> infection: WHO guidelines for low tuberculosis burden countries. European Respiratory Journal, 2015, 46, 1563-1576.	6.7	475
7	HIV Infection–Associated Tuberculosis: The Epidemiology and the Response. Clinical Infectious Diseases, 2010, 50, S201-S207.	5.8	454
8	The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2016, 16, 1269-1278.	9.1	334
9	Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies. PLoS Medicine, 2011, 8, e1000391.	8.4	328
10	Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet, The, 2012, 379, 1902-1913.	13.7	300
11	Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis. PLoS Medicine, 2012, 9, e1001270.	8.4	298
12	Global tuberculosis control: lessons learnt and future prospects. Nature Reviews Microbiology, 2012, 10, 407-416.	28.6	199
13	Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infectious Diseases, The, 2006, 6, 483-495.	9.1	132
14	Integrating tuberculosis and <scp>HIV</scp> services in low―and middleâ€income countries: a systematic review. Tropical Medicine and International Health, 2013, 18, 199-211.	2.3	113
15	TB as a cause of hospitalization and inâ€hospital mortality among people living with HIV worldwide: a systematic review and metaâ€analysis. Journal of the International AIDS Society, 2016, 19, 20714.	3.0	108
16	Opportunities and Challenges for HIV Care in Overlapping HIV and TB Epidemics. JAMA - Journal of the American Medical Association, 2008, 300, 423.	7.4	106
17	Prevention, Diagnosis, and Treatment of Tuberculosis in Children and Mothers: Evidence for Action for Maternal, Neonatal, and Child Health Services. Journal of Infectious Diseases, 2012, 205, S216-S227.	4.0	98
18	Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. Aids, 2010, 24, S57-S65.	2.2	90

#	Article	IF	CITATIONS
19	Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings. Emerging Infectious Diseases, 2018, 24, .	4.3	89
20	Epidemic of neurolathyrism in Ethiopia. Lancet, The, 1999, 354, 306-307.	13.7	84
21	Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies. Tropical Medicine and International Health, 2005, 10, 734-742.	2.3	74
22	Food-aid cereals to reduce neurolathyrism related to grass-pea preparations during famine. Lancet, The, 2003, 362, 1808-1810.	13.7	67
23	Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. Lancet HIV,the, 2018, 5, e515-e523.	4.7	66
24	HIV and tuberculosis – science and implementation to turn the tide and reduce deaths. Journal of the International AIDS Society, 2012, 15, 17396.	3.0	49
25	Latent Mycobacterium tuberculosis Infection. New England Journal of Medicine, 2015, 373, 1178-1180.	27.0	48
26	Tuberculosis elimination and the challenge of latent tuberculosis. Presse Medicale, 2017, 46, e13-e21.	1.9	48
27	Neurolathyrism risk depends on type of grass pea preparation and on mixing with cereals and antioxidants. Tropical Medicine and International Health, 2005, 10, 169-178.	2.3	47
28	Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. Aids, 2012, 26, 2121-2133.	2.2	44
29	Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. Aids, 2016, 30, 797-801.	2.2	37
30	National policies on the management of latent tuberculosis infection: review of 98 countries. Bulletin of the World Health Organization, 2018, 96, 173-184F.	3.3	36
31	Tuberculosis and HIV in people who inject drugs. Current Opinion in HIV and AIDS, 2012, 7, 345-353.	3.8	34
32	HIV and multidrug-resistant tuberculosis: overlapping epidemics. European Respiratory Journal, 2014, 44, 251-254.	6.7	29
33	Pattern and associated factors of the neurolathyrism epidemic in Ethiopia. Tropical Medicine and International Health, 2002, 7, 118-124.	2.3	28
34	Advancing global programmatic management of latent tuberculosis infection for at risk populations. European Respiratory Journal, 2016, 47, 1327-1330.	6.7	22
35	Managing tuberculosis in people who use and inject illicit drugs. Bulletin of the World Health Organization, 2013, 91, 154-156.	3.3	20
36	HIV-associated tuberculosis. International Journal of STD and AIDS, 2021, 32, 780-790.	1.1	19

HAILEYESUS GETAHUN

#	Article	IF	CITATIONS
37	Active case-finding for TB in the community: time to act. Lancet, The, 2010, 376, 1205-1206.	13.7	17
38	PEPFAR Support for the Scaling Up of Collaborative TB/HIV Activities. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, S136-S144.	2.1	17
39	Model villages: a platform for community-based primary health care. The Lancet Global Health, 2016, 4, e78-e79.	6.3	17
40	Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration. European Respiratory Journal, 2016, 47, 686-688.	6.7	17
41	3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review. European Respiratory Journal, 2018, 52, 1800395.	6.7	17
42	Prevention of tuberculosis in household members: estimates of children eligible for treatment. Bulletin of the World Health Organization, 2019, 97, 534-547D.	3.3	17
43	Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review <i>versus</i> expert opinion. European Respiratory Journal, 2015, 45, 1170-1173.	6.7	15
44	Transforming the global tuberculosis response through effective engagement of civil society organizations: the role of the World Health Organization. Bulletin of the World Health Organization, 2011, 89, 616-618.	3.3	14
45	Tuberculosis Drug Development. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1107-1113.	5.6	13
46	Neurolathyrism in Ethiopia: assessment and comparison of knowledge and attitude of health workers and rural inhabitants. Social Science and Medicine, 2002, 54, 1513-1524.	3.8	12
47	Assessing the impact of defining a global priority research agenda to address <scp>HIV</scp> â€associated tuberculosis. Tropical Medicine and International Health, 2016, 21, 1420-1427.	2.3	11
48	Numbers needed to treat to prevent tuberculosis. European Respiratory Journal, 2015, 46, 1838-1839.	6.7	9
49	Confronting TB/HIV in the era of increasing anti-TB drug resistance. Journal of the International AIDS Society, 2008, 11, 6.	3.0	8
50	Improving the prevention, diagnosis and treatment of TB among people living with HIV: the role of operational research. Journal of the International AIDS Society, 2011, 14, S5.	3.0	8
51	Comparison of urinary amino acids and trace elements (copper, zinc and manganese) of recent neurolathyrism patients and healthy controls from Ethiopia. Clinical Biochemistry, 2007, 40, 397-402.	1.9	6
52	Local innovations and country ownership for sustainable development. Bulletin of the World Health Organization, 2015, 93, 742-742.	3.3	4
53	Tackling the persistent burden of tuberculosis among people living with HIV. Journal of the International AIDS Society, 2016, 19, 21002.	3.0	4
54	Implementation of tuberculosis prevention for exposed children, Burkina Faso. Bulletin of the World Health Organization, 2018, 96, 386-392.	3.3	4

HAILEYESUS GETAHUN

#	Article	IF	CITATIONS
55	ABO blood groups, grass pea preparation, and neurolathyrism in Ethiopia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2002, 96, 700-703.	1.8	3
56	Transitioning from â€~stopping' to â€~ending' the tuberculosis epidemic. International Journal of Tuberculosis and Lung Disease, 2015, 19, 623-624.	1.2	3
57	Service integration to reduce HIV-associated TB mortality. Public Health Action, 2015, 5, 204-204.	1.2	2
58	Tailoring Treatment of Latent Tuberculosis to the Needs of Patients and Families. Annals of Internal Medicine, 2017, 167, 742.	3.9	2
59	Pattern of articles published in the Ethiopian Medical Journal. Ethiopian Medical Journal, 2002, 40, 315-23.	0.6	2
60	Paradigm shift to address drug resistant tuberculosis in people living with HIV needed, and needed now. Tropical Medicine and International Health, 2009, 14, 376-378.	2.3	1
61	Identifying priorities for HIV-associated tuberculosis research through the WHO guidelines process. Current Opinion in HIV and AIDS, 2018, 13, 538-542.	3.8	1
62	Can antiretrovirals curb southern Africa's HIV-associated TB epidemic?. Public Health Action, 2016, 6, 158-159.	1.2	0